Skip to main content
Erschienen in: Rheumatology International 3/2014

01.03.2014 | Letter to the Editor

Is there an association between Ro52/TRIM21 antibodies and rheumatoid factor in systemic sclerosis?

verfasst von: Sonal Mehra, Marie Hudson, Michael Mahler, Murray Baron, Marvin Fritzler, Canadian Scleroderma Research Group

Erschienen in: Rheumatology International | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Excerpt

Dear Editor, …
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Peene I, Meheus L, De Keyser S, Humbel R, Veys EM, De Keyser F (2002) Anti-Ro52 reactivity is an independent and additional serum marker in connective tissue disease. Ann Rheum Dis 61(10):929–933PubMedCrossRef Peene I, Meheus L, De Keyser S, Humbel R, Veys EM, De Keyser F (2002) Anti-Ro52 reactivity is an independent and additional serum marker in connective tissue disease. Ann Rheum Dis 61(10):929–933PubMedCrossRef
2.
Zurück zum Zitat Hudson M, Pope J, Mahler M, Tatibouet S, Steele R, Baron M, Canadian Scleroderma Research Group (CSRG), Fritzler M (2012) Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. Arthritis Res Ther 14(2):R50PubMedCentralPubMedCrossRef Hudson M, Pope J, Mahler M, Tatibouet S, Steele R, Baron M, Canadian Scleroderma Research Group (CSRG), Fritzler M (2012) Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. Arthritis Res Ther 14(2):R50PubMedCentralPubMedCrossRef
3.
Zurück zum Zitat Schulte-Pelkum J, Fritzler M, Mahler M (2009) Latest update on the Ro/SS-A autoantibody system. Autoimmun Rev 8(7):632–637PubMedCrossRef Schulte-Pelkum J, Fritzler M, Mahler M (2009) Latest update on the Ro/SS-A autoantibody system. Autoimmun Rev 8(7):632–637PubMedCrossRef
4.
Zurück zum Zitat Takahata M, Bohgaki M, Tsukiyama T, Kondo T, Asaka M, Hatakeyama S (2008) Ro52 functionally interacts with IgG1 and regulates its quality control via the ERAD system. Mol Immunol 45(7):2045–2054PubMedCrossRef Takahata M, Bohgaki M, Tsukiyama T, Kondo T, Asaka M, Hatakeyama S (2008) Ro52 functionally interacts with IgG1 and regulates its quality control via the ERAD system. Mol Immunol 45(7):2045–2054PubMedCrossRef
5.
Zurück zum Zitat Retamozo S, Akasbi M, Brito-Zeron P, Bosch X, Bove A, Perez-de-Lis M, Jimenez I, Soto-Cardenas MJ, Gandia M, Diaz-Lagares C, Vinas O, Siso A, Perez-Alvarez R, Yague J, Ramos-Casals M (2012) Anti-Ro52 antibody testing influences the classification and clinical characterisation of primary Sjogren’s syndrome. Clin Exp Rheumatol 30(5):686–692PubMed Retamozo S, Akasbi M, Brito-Zeron P, Bosch X, Bove A, Perez-de-Lis M, Jimenez I, Soto-Cardenas MJ, Gandia M, Diaz-Lagares C, Vinas O, Siso A, Perez-Alvarez R, Yague J, Ramos-Casals M (2012) Anti-Ro52 antibody testing influences the classification and clinical characterisation of primary Sjogren’s syndrome. Clin Exp Rheumatol 30(5):686–692PubMed
6.
Zurück zum Zitat Dugar M, Cox S, Limaye V, Gordon TP, Roberts-Thomson PJ (2010) Diagnostic utility of anti-Ro52 detection in systemic autoimmunity. Postgrad Med J 86(1012):79–82PubMedCrossRef Dugar M, Cox S, Limaye V, Gordon TP, Roberts-Thomson PJ (2010) Diagnostic utility of anti-Ro52 detection in systemic autoimmunity. Postgrad Med J 86(1012):79–82PubMedCrossRef
7.
Zurück zum Zitat Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Yazawa N, Tamaki K (2004) Rheumatoid factor isotypes and anti-agalactosyl IgG antibodies in systemic sclerosis. Br J Dermatol 151(4):803–808PubMedCrossRef Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Yazawa N, Tamaki K (2004) Rheumatoid factor isotypes and anti-agalactosyl IgG antibodies in systemic sclerosis. Br J Dermatol 151(4):803–808PubMedCrossRef
8.
Zurück zum Zitat Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Tamaki K (2005) Clinical and laboratory features of scleroderma patients developing skeletal myopathy. Clin Rheumatol 24(2):99–102PubMedCrossRef Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Tamaki K (2005) Clinical and laboratory features of scleroderma patients developing skeletal myopathy. Clin Rheumatol 24(2):99–102PubMedCrossRef
9.
Zurück zum Zitat Ueda-Hayakawa I, Hasegawa M, Kumada S, Tanaka C, Komura K, Hamaguchi Y, Takehara K, Fujimoto M (2010) Usefulness of anti-cyclic citrullinated peptide antibody and rheumatoid factor to detect rheumatoid arthritis in patients with systemic sclerosis. Rheumatology (Oxford) 49(11):2135–2139CrossRef Ueda-Hayakawa I, Hasegawa M, Kumada S, Tanaka C, Komura K, Hamaguchi Y, Takehara K, Fujimoto M (2010) Usefulness of anti-cyclic citrullinated peptide antibody and rheumatoid factor to detect rheumatoid arthritis in patients with systemic sclerosis. Rheumatology (Oxford) 49(11):2135–2139CrossRef
10.
Zurück zum Zitat Pakozdi A, Nihtyanova S, Moinzadeh P, Ong VH, Black CM, Denton CP (2011) Clinical and serological hallmarks of systemic sclerosis overlap syndromes. J Rheumatol 38(11):2406–2409PubMedCrossRef Pakozdi A, Nihtyanova S, Moinzadeh P, Ong VH, Black CM, Denton CP (2011) Clinical and serological hallmarks of systemic sclerosis overlap syndromes. J Rheumatol 38(11):2406–2409PubMedCrossRef
Metadaten
Titel
Is there an association between Ro52/TRIM21 antibodies and rheumatoid factor in systemic sclerosis?
verfasst von
Sonal Mehra
Marie Hudson
Michael Mahler
Murray Baron
Marvin Fritzler
Canadian Scleroderma Research Group
Publikationsdatum
01.03.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 3/2014
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-013-2728-x

Weitere Artikel der Ausgabe 3/2014

Rheumatology International 3/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.